Protease Inhibitors for Patients With HIV-1 Infection: A Comparative Overview.
作者信息
Hughes Peter J, Cretton-Scott Erika, Teague Ami, Wensel Terri M
出版信息
P T. 2011 Jun;36(6):332-45.
Abstract
摘要
相似文献
1
2
Effect of human immunodeficiency virus-1 protease inhibitors on the clearance of human herpesvirus 8 from blood of human immunodeficiency virus-1-infected patients.人类免疫缺陷病毒1型蛋白酶抑制剂对人类免疫缺陷病毒1型感染患者血液中人类疱疹病毒8清除率的影响。
J Med Virol. 2000 Dec;62(4):416-20. doi: 10.1002/1096-9071(200012)62:4<416::aid-jmv4>3.0.co;2-z.
3
Analysis of the S3 and S3' subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV in vitro and ex vivo.猫免疫缺陷病毒（FIV）蛋白酶S3和S3'亚位点特异性分析：一种对FIV、SIV和HIV在体外和体内均有效的广谱蛋白酶抑制剂的研发。
Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):939-44. doi: 10.1073/pnas.95.3.939.
4
5
Antiviral activity of human immunodeficiency virus type 1 protease inhibitors in a single cycle of infection: evidence for a role of protease in the early phase.1型人类免疫缺陷病毒蛋白酶抑制剂在单次感染周期中的抗病毒活性：蛋白酶在早期阶段作用的证据
J Virol. 1994 Feb;68(2):757-65. doi: 10.1128/JVI.68.2.757-765.1994.
6
Phenotypic hypersusceptibility to multiple protease inhibitors and low replicative capacity in patients who are chronically infected with human immunodeficiency virus type 1.1型人类免疫缺陷病毒慢性感染患者对多种蛋白酶抑制剂的表型超敏感性及低复制能力
J Virol. 2005 May;79(10):5907-13. doi: 10.1128/JVI.79.10.5907-5913.2005.
7
Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor.安普那韦：一种新型人类免疫缺陷病毒1型蛋白酶抑制剂。
Clin Ther. 2000 May;22(5):549-72. doi: 10.1016/S0149-2918(00)80044-2.
8
Hepatotoxicity and antiretroviral therapy with protease inhibitors: A review.肝毒性与蛋白酶抑制剂抗逆转录病毒疗法：综述
Dig Liver Dis. 2006 Jun;38(6):363-73. doi: 10.1016/j.dld.2006.01.020. Epub 2006 May 2.
9
Polymorphism of the human immunodeficiency virus type 1 (HIV-1) protease gene and response of HIV-1-infected patients to a protease inhibitor.人类免疫缺陷病毒1型（HIV-1）蛋白酶基因多态性与HIV-1感染患者对蛋白酶抑制剂的反应
J Clin Microbiol. 1999 Sep;37(9):2910-2. doi: 10.1128/JCM.37.9.2910-2912.1999.
10
An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection.蛋白酶抑制剂可阻断人类和猿猴免疫缺陷病毒的成熟及感染传播。
Proc Natl Acad Sci U S A. 1990 Oct;87(19):7472-6. doi: 10.1073/pnas.87.19.7472.
引用本文的文献
1
Navigating Lipodystrophy: Insights from Laminopathies and Beyond.脂肪代谢障碍的探索：从层粘连蛋白病到其他疾病的启示
Int J Mol Sci. 2024 Jul 23;25(15):8020. doi: 10.3390/ijms25158020.
2
Drug-Induced Acute Pancreatitis in Adults: Focus on Antimicrobial and Antiviral Drugs, a Narrative Review.成人药物性急性胰腺炎：聚焦于抗菌药物和抗病毒药物，一篇叙述性综述
Antibiotics (Basel). 2023 Sep 29;12(10):1495. doi: 10.3390/antibiotics12101495.
3
Seawater fungi-derived compound screening to identify novel small molecules against dengue virus NS5 methyltransferase and NS2B/NS3 protease.筛选海水真菌衍生化合物以鉴定针对登革病毒NS5甲基转移酶和NS2B/NS3蛋白酶的新型小分子。
Inform Med Unlocked. 2022;30:100932. doi: 10.1016/j.imu.2022.100932. Epub 2022 Mar 26.
4
Comparative analysis of the unbinding pathways of antiviral drug Indinavir from HIV and HTLV1 proteases by supervised molecular dynamics simulation.通过有监督的分子动力学模拟对抗病毒药物茚地那韦从 HIV 和 HTLV1 蛋白酶中解吸的途径进行比较分析。
PLoS One. 2021 Sep 27;16(9):e0257916. doi: 10.1371/journal.pone.0257916. eCollection 2021.
5
Management of Antiretroviral Therapy with Boosted Protease Inhibitors-Darunavir/Ritonavir or Darunavir/Cobicistat.使用增强型蛋白酶抑制剂（达芦那韦/利托那韦或达芦那韦/考比司他）进行抗逆转录病毒治疗的管理
Biomedicines. 2021 Mar 18;9(3):313. doi: 10.3390/biomedicines9030313.
6
Atazanavir / ritonavir versus Lopinavir / ritonavir-based combined antiretroviral therapy (cART) for HIV-1 infection: a systematic review and meta-analysis.阿扎那韦/利托那韦与洛匹那韦/利托那韦为基础的联合抗逆转录病毒治疗（cART）用于治疗 HIV-1 感染：系统评价和荟萃分析。
Afr Health Sci. 2020 Mar;20(1):91-101. doi: 10.4314/ahs.v20i1.14.
7
Pharmacogenomics of Antiretroviral Drug Metabolism and Transport.抗逆转录病毒药物代谢与转运的药物基因组学
Annu Rev Pharmacol Toxicol. 2021 Jan 6;61:565-585. doi: 10.1146/annurev-pharmtox-021320-111248. Epub 2020 Sep 22.
8
Effect of transcription inhibition and generation of suppressive viral non-coding RNAs.转录抑制和抑制性病毒非编码 RNA 的产生的影响。
Retrovirology. 2019 Apr 29;16(1):13. doi: 10.1186/s12977-019-0475-0.
9
Design and Synthesis of Potent HIV-1 Protease Inhibitors Containing Bicyclic Oxazolidinone Scaffold as the P2 Ligands: Structure-Activity Studies and Biological and X-ray Structural Studies.含双环恶唑烷酮骨架作为 P2 配体的高效 HIV-1 蛋白酶抑制剂的设计与合成：构效关系研究及生物和 X 射线结构研究。
J Med Chem. 2018 Nov 8;61(21):9722-9737. doi: 10.1021/acs.jmedchem.8b01227. Epub 2018 Oct 24.
10
Design and Synthesis of Highly Potent HIV-1 Protease Inhibitors Containing Tricyclic Fused Ring Systems as Novel P2 Ligands: Structure-Activity Studies, Biological and X-ray Structural Analysis.含三环稠合环系作为新型 P2 配体的高效抗 HIV-1 蛋白酶抑制剂的设计与合成：构效关系研究、生物学及 X 射线结构分析。
J Med Chem. 2018 May 24;61(10):4561-4577. doi: 10.1021/acs.jmedchem.8b00298. Epub 2018 May 15.
本文引用的文献
1
Contemporary costs of HIV healthcare in the HAART era.抗逆转录病毒治疗时代下 HIV 医疗保健的当代成本。
AIDS. 2010 Nov 13;24(17):2705-15. doi: 10.1097/QAD.0b013e32833f3c14.
2
Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States.在美国，达芦那韦/利托那韦与其他利托那韦增强型蛋白酶抑制剂用于一线治疗HIV-1感染的成本效益比较分析。
HIV Clin Trials. 2010 May-Jun;11(3):133-44. doi: 10.1310/hct1103-133.
3
Protease inhibitor-based antiretroviral therapy in treatment-naive HIV-1-infected patients: the evidence behind the options.基于蛋白酶抑制剂的抗逆转录病毒疗法在初治 HIV-1 感染患者中的应用：各种选择的依据。
J Antimicrob Chemother. 2010 Jun;65(6):1094-9. doi: 10.1093/jac/dkq130. Epub 2010 Apr 23.
4
The frequency and reasons for antiretroviral switching with specific antiretroviral associations: the SWITCH study.抗逆转录病毒药物转换的频率和原因与特定的抗逆转录病毒药物联合治疗：SWITCH 研究。
Antiviral Res. 2010 May;86(2):227-9. doi: 10.1016/j.antiviral.2010.03.001. Epub 2010 Mar 6.
5
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.在病毒血症得到抑制的稳定 HIV 感染者中，换用拉替拉韦方案与继续使用洛匹那韦/利托那韦方案（SWITCHMRK 1 和 2）：两项多中心、双盲、随机对照试验。
Lancet. 2010 Jan 30;375(9712):396-407. doi: 10.1016/S0140-6736(09)62041-9. Epub 2010 Jan 12.
6
Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.替拉那韦/利托那韦每日 1 次与洛匹那韦/利托那韦每日 2 次，分别联合替诺福韦和恩曲他滨，用于治疗初治 HIV-1 感染患者的疗效和安全性：CASTLE 研究 96 周结果。
J Acquir Immune Defic Syndr. 2010 Mar;53(3):323-32. doi: 10.1097/QAI.0b013e3181c990bf.
7
Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance.15 年的 HIV 蛋白酶抑制剂：提高耐药屏障。
Antiviral Res. 2010 Jan;85(1):59-74. doi: 10.1016/j.antiviral.2009.10.003. Epub 2009 Oct 22.
8
Pharmacogenetics of antiretrovirals.抗逆转录病毒药物的药物遗传学。
Antiviral Res. 2010 Jan;85(1):190-200. doi: 10.1016/j.antiviral.2009.09.001. Epub 2009 Sep 8.
9
Efficacy and safety of atazanavir-ritonavir plus abacavir-lamivudine or tenofovir-emtricitabine in patients with hyperlipidaemia switched from a stable protease inhibitor-based regimen including one thymidine analogue.对于从包含一种胸腺嘧啶核苷类似物的稳定蛋白酶抑制剂方案转换过来的高脂血症患者，阿扎那韦-利托那韦联合阿巴卡韦-拉米夫定或替诺福韦-恩曲他滨的疗效和安全性。
AIDS Patient Care STDS. 2009 Sep;23(9):691-7. doi: 10.1089/apc.2009.0039.
10
Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.福沙普那韦/利托那韦治疗晚期HIV疾病（TRIAD）：一项针对具有抗逆转录病毒耐药性的HIV-1感染患者，对比高剂量、双重增效或标准剂量福沙普那韦/利托那韦的随机研究。
J Antimicrob Chemother. 2009 Aug;64(2):398-410. doi: 10.1093/jac/dkp198. Epub 2009 Jun 10.
Zotero 插件